m+Medelevator.RU
← Поиск публикаций
Health science reports · 2026

Liver Transplantation Outcomes in Crigler-Najjar Syndrome in Iran: A Single-Center Retrospective Cohort Study Over 20 Years.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Teimoury Sajad, Beyzaei Zahra, Shamsaeefar Alireza, Kazemi Kurosh, Nikeghbalian Saman, Malekhosseini Seyed-Ali, Geramizadeh Bita

Аннотация

BACKGROUND AND AIMS: Crigler-Najjar Syndrome (CNS) is a rare autosomal recessive disorder caused by uridine diphosphate glucuronosyltransferase (UGT1A1) deficiency, leading to unconjugated hyperbilirubinemia. Without treatment, patients are at high risk of kernicterus and irreversible neurological damage. Liver transplantation (LT) is the only curative option. This study aims to evaluate long-term outcomes of LT in CNS patients over a 20-year period in Iran.

METHODS: In this retrospective cohort study, we analyzed 69 patients with CNS who underwent LT between 2000 and 2023 at Namazi Hospital and Abu Ali Sina Transplant Center in Shiraz, Iran. Long-term follow-up data, graft function, patient survival, and pre- and post-LT outcomes were evaluated.

RESULTS: Posttransplantation, bilirubin metabolism and liver function normalized rapidly. Within the first year, the overall mortality rate was 14.5%, mainly due to graft failure and sepsis. Late mortality (2.9%) was predominantly linked to chronic rejection and infections.

CONCLUSIONS: LT remains a definitive curative option for patients with CNS. However, postoperative complications, particularly hematologic and renal dysfunction, remain significant concerns. These findings underscore the importance of ongoing monitoring and optimization of post-LT care. Furthermore, the lack of consensus regarding ideal timing for LT highlights the need for future prospective studies to better inform clinical decision-making.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты